Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KYMR 
Kymera Therapeutics Inc (KYMR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: KYMR (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $73.23
1 Year Target Price $73.23
| 14 | Strong Buy |
| 3 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 119.05% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.31B USD | Price to earnings Ratio - | 1Y Target Price 73.23 |
Price to earnings Ratio - | 1Y Target Price 73.23 | ||
Volume (30-day avg) 20 | Beta 2.3 | 52 Weeks Range 19.45 - 63.96 | Updated Date 11/5/2025 |
52 Weeks Range 19.45 - 63.96 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.49 |
Earnings Date
Report Date 2025-10-29 | When Before Market | Estimate -0.8613 | Actual -0.94 |
Profitability
Profit Margin - | Operating Margin (TTM) -736.82% |
Management Effectiveness
Return on Assets (TTM) -19.92% | Return on Equity (TTM) -33.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3424134432 | Price to Sales(TTM) 95.8 |
Enterprise Value 3424134432 | Price to Sales(TTM) 95.8 | ||
Enterprise Value to Revenue 76.58 | Enterprise Value to EBITDA -9.49 | Shares Outstanding 71949027 | Shares Floating 46969631 |
Shares Outstanding 71949027 | Shares Floating 46969631 | ||
Percent Insiders 2.51 | Percent Institutions 112.76 |
Upturn AI SWOT
Kymera Therapeutics Inc
Company Overview
History and Background
Kymera Therapeutics Inc. was founded in 2016. It focuses on developing protein degradation therapies using its proprietary targeted protein degradation platform, Pegasus. The company's initial focus was on oncology and immunology.
Core Business Areas
- Targeted Protein Degradation: Kymera's core business revolves around its Pegasus platform, designed to selectively degrade disease-causing proteins. Their focus is on discovering and developing small molecule degraders.
Leadership and Structure
Nello Mainolfi, PhD, is the President and CEO. The company has a typical biotech organizational structure with teams dedicated to research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- KT-474 (Irac1 degrader): KT-474 is Kymera's lead clinical program, targeting IRAK4 degradation for immune-inflammatory diseases. Currently in Phase 2 clinical trials. Market share is not applicable as this is pre-commercial. Competitors: Companies developing IRAK4 inhibitors or other treatments for similar inflammatory diseases (e.g., Roche, Sanofi). No revenue generated yet.
- STAT3 Degrader Program: The STAT3 degrader program is focused on oncology. Currently in Phase 1 clinical trials. Market share is not applicable. Competitors: Companies developing STAT3 inhibitors or other oncology treatments (e.g., AstraZeneca, Novartis). No revenue generated yet.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing a shift towards targeted therapies and precision medicine. Protein degradation is an emerging field with high potential but also high risk.
Positioning
Kymera is a leading company in the targeted protein degradation space, with a strong proprietary platform and a focus on high-value targets. Competitive advantage lies in its ability to selectively degrade proteins using small molecules.
Total Addressable Market (TAM)
The total market value is substantial, potentially reaching tens of billions of dollars across oncology and immunology applications. Kymera is positioned to capture a portion of this market through successful clinical development and commercialization of its degrader therapies.
Upturn SWOT Analysis
Strengths
- Proprietary Pegasus protein degradation platform
- Strong scientific leadership
- Focus on high-value targets
- Partnerships with major pharmaceutical companies
- Promising early clinical data
Weaknesses
- Early-stage clinical development
- High risk of clinical trial failure
- Reliance on funding and partnerships
- Limited internal manufacturing capabilities
- Limited revenue streams
Opportunities
- Expansion of the Pegasus platform to new targets and disease areas
- Potential for breakthrough therapies in oncology and immunology
- Strategic partnerships and acquisitions
- Advancements in protein degradation technologies
- Favorable regulatory environment for innovative therapies
Threats
- Clinical trial failures
- Competition from other protein degradation companies
- Regulatory hurdles
- Intellectual property disputes
- Funding challenges
Competitors and Market Share
Key Competitors
- ARVN
- CRIS
- CCXI
Competitive Landscape
Kymera has a strong position in the protein degradation field, but faces competition from other companies developing similar therapies. Kymera's Pegasus platform and partnerships give it a competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by expansion of the pipeline, clinical trial progress, and strategic partnerships.
Future Projections: Future growth is dependent on successful clinical development and commercialization of its lead programs. Analyst estimates vary but generally project significant revenue growth in the coming years if clinical trials are successful.
Recent Initiatives: Recent initiatives include advancing KT-474 into Phase 2 trials and expanding partnerships with pharmaceutical companies.
Summary
Kymera Therapeutics is an early-stage biotechnology company focused on protein degradation therapies. The company has a strong platform and promising clinical programs, but faces significant risks associated with drug development. Their financial stability is dependent on funding and partnership agreements, and the success of their clinical trials will dictate their future growth trajectory. The company needs to continue to look out for competitive threats.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Kymera Therapeutics Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual due diligence and consultation with a financial advisor. Market share estimates are approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kymera Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-08-21 | Co-Founder, President, CEO & Director Dr. Nello Mainolfi M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 218 | Website https://www.kymeratx.com |
Full time employees 218 | Website https://www.kymeratx.com | ||
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.